Identifying potential adverse drug events prior to their onset can be the difference between clinical success and failure. CQuentia’s proprietary pioneering technology, developed in part by incorporating the guidelines as defined by the Clinical Pharmacogenetics Implementation Consortium (CPIC), provides actionable insight into drug efficacy based directly on a patient’s unique genetic profile.

CQuentia’s Pharmacogenomic (PGx) testing program combined with CQuentia’s data analytics has been shown to reduce adverse gene-drug, drug-drug, and drug-disease events. PGx testing enables a pharmacist to reduce opioid use and the prescribing of inappropriate medications, providing an improved and safer medication regimen for the patient. Our innovative Pharmacogenomic Testing Program streamlines your medication therapy management process by utilizing the patient’s genetic profile to significantly reduce the risk of adverse drug events before, during, and after the clinical visit.

Find out what other leading institutions are saying about CQuentia.

Contact us to enlist your institution in a no-risk trial of our PGx program and be our partner in improving global health care by accelerating the impact of genomics on patient care.

CQuentia, more than a lab, more than a test. The leaders in the new frontier of genomic testing and personalized medicine.

Meet the expertly-designed leadership teams that make CQuentia’s mission and work possible.

Ready to speak with our experts?

CALL NOW: (855) 230-6461


Contact Us

Click to Hide Advanced Floating Content